Health
STAT+: With $173 million, new startup takes aim at sickle cell
Publication: STAT
Author: Jason Mast
Source published: 17/11/2026, 12:00:00 UTC
Briefing created: 17/11/2026, 14:22:52 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 17/11/2026, 14:21:24 UTC.
Briefings
Biotech entrepreneur Romesh Subramanian announced the founding of startup Marrow Therapeutics on November 17, 2026, to develop a treatment for sickle cell disease. The company secured $173 million in Series A and B funding from Scion Life Sciences, venBio, and OrbiMed. Subramanian stated the goal is to achieve efficacy comparable to gene therapy while avoiding its drawbacks, though the company expects the results to be proven only after clinical trials.
Key points
- Romesh Subramanian founded Marrow Therapeutics on November 17, 2026, to develop a sickle cell treatment.
- The startup secured $173 million in Series A and B funding from Scion Life Sciences, venBio, and OrbiMed.
Context
Marrow Therapeutics aims to create a treatment for sickle cell disease that matches the efficacy of gene therapy but without its associated risks. The company received significant venture capital to advance its research into a potential cure for the condition.
Limitations
The evidence is limited to the announcement of the startup and its initial funding sources. Clinical trial results, efficacy data, and long-term patient outcomes are not provided in the source material.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 17/11/2026, 14:22:52 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeid6mhvlxb5ulrmvitgxqlih4lyb4v4vwfugzkgv6xcc2ytkd53qpm